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This executive summary briefly describes the overall
goals and content of the report on safety consideration for
stereotactic radiosurgery (SRS) and stereotactic body
radiation therapy (SBRT), but is very limited in length
and content. This abridged version is not intended to
replace the full length report but rather to highlight key
recommendations. All readers are referred to the full report
published online only at www.practicalradonc.org.
This report on SRS and SBRT is part of a series of white
papers addressing patient safety commissioned by the
American Society for Radiation Oncology (ASTRO). This
document was approved by the ASTROBoard of Directors
on April 11, 2011. It has been endorsed by the American
Association of Physicists in Medicine, the American
Society of Radiologic Technologists, and the American
Association of Medical Dosimetrists. It has been reviewed
and accepted by the American College of Radiology's
Commission on Radiation Oncology.lsevier Inc. Open access under CC BY-NC-ND license. 
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organizations in North America have previously published
several “guidance” reports on various aspects of SRS/
SBRT.1-6 Several recent national and international efforts
that specifically address safety in radiotherapy also played
a prominent role in formulating the recommendations in
this report.7-11
It is important to understand that the SRS/SBRT
measures described and recommended in this document
are just one component of a broader process of ongoing
quality assurance (QA) that includes periodic review of
errors, incidents, and near misses for the purpose of
developing or refining standard operating procedures that
minimize the risk of such events. Similarly, detailed
equipment specifications and tolerances have been
described in a number of documents, and while some
of these aspects may be reiterated and emphasized in this
paper, it is not intended to be comprehensive in this
regard. Rather, this report builds on these and other
documents, broadly addressing SRS/SBRT delivery with
a primary focus on programmatic elements and human
processes that can identify and correct potential sources
of error, particularly those which can result in cata-
strophic consequences.
SRS has been used for decades in the treatment of brain
metastases and a variety of other cranial neoplasms and
functional disorders; its efficacy and toxicity profile have
been well described and its role well established as an
efficient and effective means of achieving a high rate of
local control and, in some settings, improved survival.12
Acute side effects, including headache, pin-site infection,
and short-term exacerbation of neurologic symptoms are
relatively minor and readily managed. Late side effects,
including radiation necrosis, brain edema, and exacerba-
tion of preexisting (or development of new) neurologic
deficits occur in less than 5% of patients.13 Five-year local
control rates following SRS or FSRT [fractionated
stereotactic radiation therapy] for acoustic neuromas
exceed 95%.14 Current doses of 13 Gy (single fraction)
or ∼50 Gy (in 1.8-Gy fractions) yield excellent rates of
hearing preservation and very low rates of facial and
trigeminal neuropathies. Similarly, excellent rates of local
control can be expected following either SRS or FSRT
treatment of meningiomas.15-17
SBRT is a much more recent modality, with unique
technological and clinical considerations. Nevertheless,
initial clinical results from prospective single institution,
and more recently, multi-institutional clinical trials of
SBRT have documented similar high rates of tumor
control coupled with a low incidence of serious toxicity
despite the high dose fractions of radiation being
delivered. The efficacy of SBRT is established for a
variety of clinical indications as a primary treatment for
selected early-stage cancers or as treatment for discrete
tumors in patients with oligometastatic disease, selected
benign neoplasms in or near the central nervous system, orrecurrent cancer in previously irradiated regions. The
utility of SBRT is perhaps best exemplified in the case of
inoperable early-stage lung cancer,18 where the 3-year
primary tumor control rate of 98% is roughly twice what
would be expected from conventional RT given over a
6- to 7-week period. To date, reports of prospective
clinical trials of SBRT have typically documented similar
high rates of tumor control, coupled with a low incidence
of serious toxicity, despite the high-dose fractions of
radiation given to tumors.19-29 This favorable therapeutic
ratio is achieved because SBRT couples a high degree of
anatomic targeting accuracy and reproducibility with very
high doses of precisely delivered radiation, thereby maxi-
mizing the cell-killing effect on the target(s) while mini-
mizing radiation-related injury in adjacent normal tissues.
Given that very high-dose fractions of radiation are
delivered, the margin of error for SRS and SBRT is
significantly smaller than that of conventional radiother-
apy and therefore special attention and diligence is
required. A small error in target localization for any 1
fraction risks undertreatment of portions of the tumor by
20% or more, and inadvertent overdosage of adjacent
normal tissues could escalate the risk of serious injury to a
much greater degree than an equivalent treatment error in a
course of radiotherapy where a substantially lower dose
per fraction is used.25,30-34
Many in the community are aware of recent events,
publicized in the media, in which serious errors have
occurred. These include the following: a calibration error
on a radiosurgery linac that affected 77 patients in Florida
in 2004-2005; similar errors in measurement of output
factors affecting 145 patients in Toulouse, France in 2006-
2007,35-37 and 152 patients in Springfield, MO from 2004
to 2009; an error in a cranial localization accessory that
affected 7 centers in the U.S. and Europe; and errors in
failure to properly set backup jaws for treatments using
small circular collimators affecting a single arteriovenous
malformation patient at an institution in France,36 and
3 patients at an institution in Evanston, IL.38
While no side effects related to the Florida calibration
error have been reported, that is not the case with several of
the other events. Gourmelon et al reported a 31%
12-month actuarial rate of trigeminal neuropathy in
32 acoustic neuroma patients overdosed in the Toulouse
accident.37 In contrast, despite a mean overdose of 61.2%,
no treatment-related morbidity was observed in the
33 patients treated for brain metastases.35 The French
patient treated with the incorrect backup collimator setting
developed an oeso-tracheal fistula requiring surgery,
experienced a hemorrhage, and subsequently died.36 One
of the 3 Evanston patients, treated for trigeminal neuralgia,
is described as being in a vegetative state.38
Further, radiosurgery errors are not limited to any
particular technology. As an example, challenges in
accurate measurement of output factors such as those
encountered on linacs in Toulouse, France and Springfield,
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1998, the output factor for a 4-mm gamma collimator was
corrected by approximately 10%, from 0.80 to 0.87, by the
manufacturer.39-40 A review of the Nuclear Regulatory
Commission Radiation Event Notification Report database
yielded 13 gamma-based radiosurgery-related events from
2005 to present, 12 of which resulted in a deviation from
the original prescription. Seven of the events involved the
treatment of the wrong location, while 3 events involved
delivery of an incorrect dose. While patient outcome is not
described on the Nuclear Regulatory Commission site,
several of the events listed, including treatment of the
wrong location with single fraction doses as high as 90 Gy,
would likely be accompanied by significant morbidity.
Wrong-site errors continue to plague all medical disci-
plines and are not unique to radiotherapy.41
The accidents described can largely be attributed to
human error, mirroring the radiotherapy experience
throughout the United Kingdom, in which only 2 out of
181 incidents reported since 2000 were determined to be
nonrelated to human error.8 However, other factors also
contributed. These include limits in equipment safety
design and the inadequacy of systems and procedures to
ensure that the stereotactic treatment was robust to the
sources of error that eventually contributed to failure.
Clearly then, improvement in human knowledge, training
standards, and implementation of robust QA processes are
needed to minimize these errors, which in the case of SRS
and SBRT, can have catastrophic consequences. Recom-
mendations designed to guard against catastrophic failure
in SRS and SBRT are provided in Appendix 1 of the
online document.Fundamental elements of SRS and SBRT
safety and quality
It is important to emphasize that SRS and SBRT are not
1 treatment technique or modality. The implementation
and accompanying requirements for immobilization,
simulation, treatment planning, delivery, and quality
assurance can vary significantly with disease site. Clinical
and technical proficiency for one site (eg, spine) does not
always translate to proficiency in another site (eg, lung).
This complex nature of the stereotactic treatment process,
and the consequences of errors when delivering high-dose
fractions of radiation, mandates a systematic and prospec-
tive approach to each disease site. Many of the overall
recommendations of the 2008 document Towards Safer
Radiotherapy8 are appropriate for SRS and SBRT
programmatic development, including the following: a
multidisciplinary working environment with a culture that
fosters clear communication and guards against inappro-
priate interruptions; careful planning and thorough risk
assessment when introducing new techniques and tech-nologies; a thorough review of all resources including
staffing levels and skills; thorough training of all
personnel, to include training in quality management and
safety practices in addition to program-specific education;
development of quality assurance processes that encom-
pass all clinical and technical program aspects; and
development of checklists, processes for documentation
and reporting, peer review, regular review of processes and
procedures, updating of clinical guidelines and recom-
mendations, ongoing needs assessment, and continuous
quality improvement.
Personnel considerations
SRS and SBRT require a large commitment of
resources. Personnel resources required for proper oper-
ation of an SBRT program can therefore be expected to be
significantly greater than for a traditional radiation therapy
program.6,42 Further, SRS and SBRT require the coordi-
nated efforts of a team of properly trained individuals who
assume essential roles during the patient evaluation and
treatment process.4-8 In addition to clinic nurses and other
staff who provide general support for all patients, the
essential personnel for SRS/SBRT include radiation
oncologists, medical physicists, dosimetrists, and radiation
therapists. Other physicians may participate in the care of
patients undergoing SRS or SBRT by offering assistance
derived from their own subspecialty training and expertise;
examples include neurosurgeons, pulmonologists, hepa-
tologists, and oncologic surgeons. Because the resources
required to implement and manage an SRS/SBRT program
are significant, institutional administrators must be part of
the overall team. All program personnel must demonstrate
initial attainment of knowledge and competence in their
respective discipline through graduation from an approved
educational program, board certification, and licensure as
appropriate. Training on SRS/SBRT technologies and
their specific clinical application, including training
provided by the equipment vendor(s), is an essential
program element; all program individuals must receive
initial SRS/SBRT-specific training for each disease site,
and must participate in SRS/SBRT-specific continuing
medical education.
Treatment of various disease sites should be considered
within the context of nationally accepted clinical stan-
dards. Based on program goals and patient selection
criteria, it is likely that treatment guidelines and pro-
cedures will be site-specific. Prior to initiating an SRS or
SBRT program, this report strongly recommends that
plans for patient selection and treatment guidelines be
developed and clearly documented within each institution.
Technical considerations
SRS and SBRT require the use of technology at a
standard above that routinely considered minimally
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guided radiotherapy applications. The extreme demands
imposed by the ablative paradigm of dose delivery amplify
concerns over the volume of tissue irradiated to high doses
as well as doses in serial organs and regions near the skin
that may otherwise be ignored. To achieve these demands,
small margins around the clinical target volume are
necessary to such an extent that conventional radiographic
localization based on bony anatomy is generally insuffi-
cient. A comprehensive image guidance and motion
management strategy needs to be applied and maintained
with sufficient technology and procedures to ensure safe
and effective positioning for treatment. Furthermore, the
dose distributions considered acceptable for SRS and
SBRT require the use of large numbers of non-opposing
beams, often inclusive of multiple non-axial approaches,
to achieve the dosimetric goal of confining the high-dose
region to the volume of interest while effectively
minimizing peripheral dose.43,44 Due to needs of clearance
for beam angles and imaging, isocenter placement may be
nontraditional. Dose needs to be calculated accurately
through complex heterogeneities and represented over the
entire irradiated volume.
SRS/SBRT begins to deviate from conventional
treatments at simulation. Typical immobilization equip-
ment for SBRT includes custom-formed devices that
cover a large extent of the patient above and below the
tumor (eg, evacuated bean bags). The use of ancillary
localization and position monitoring technologies, such
as surface imaging techniques, implanted radiographic
markers, and electromagnetic transponders, may play a
role in specific disease sites. For each of these devices
and indications for use, the operational team (radiother-
apy technologist, MD, physicist) should establish pro-
cedures for assessing the residual positioning uncertainty
that is possible when combining these immobilization
means with specific image guidance strategies. Imaging
needs for simulation and planning may include detailed
motion estimation (eg, 4-dimensional computed tomog-
raphy [4DCT]), as well as inclusion of enhanced soft
tissue (magnetic resonance imaging), or metabolic
(positron emission) information. Paraspinal SBRT may
require enhanced visualization of the spinal cord (eg,
through MR or CT myelography).
The treatment planning environment must be capable
of supporting multimodality and multidimensional input
data for SRS and SBRT planning. Specifically, magnetic
resonance imaging, positron emission tomography, and
multiple CT scans (eg, non-contrast and contrast, 4D)
must be able to be combined in an accurate manner to
facilitate target and normal tissue definition, to establish
a patient data set for use in image guidance, and to
generate an appropriate density grid for dose calculation.
The planning system must be able to support dose
calculation algorithms that represent dose deposition in
the face of heterogeneities with sufficient accuracy.Commercial planning systems using pencil beam
algorithms generally do not meet this requirement.
Demonstration of calculation accuracy during the
commissioning process through an independent dosimet-
ric check of a planned and irradiated phantom containing
heterogeneities, by an independent entity such as the
Radiological Physics Center, is strongly recommended
prior to initiating an SBRT program.
Image-guided localization is increasingly used in SRS
(ie, frameless radiosurgery) and is a prerequisite for all
SBRT applications. A comprehensive image guidance
and motion management strategy, therefore, needs to be
applied and maintained with sufficient technology and
procedures to ensure safe and effective positioning for
treatment. Ideally, this guidance should involve tumor-
based positioning at the start of each treatment fraction.
In the absence of direct tumor localization, reliable soft
tissue surrogates (eg, implanted fiducial markers) may be
necessary as a means of estimating position. Conven-
tional radiographic localization based on bony anatomy
is generally insufficient to meet the precision demands
of stereotactic treatments for soft tissue targets. Appro-
priate equipment for localization (eg, cone beam CT or
other 3D image-based method) must be used and
maintained with sufficient quality assurance procedures
to ensure the usefulness (image quality) and accuracy of
positioning. In addition to pre-treatment positioning, the
management of intra-fraction patient body movement as
well as physiological motions such as breathing must be
accounted for. Some examples of such technologies
include in-room surface monitoring systems, fluoroscop-
ic observation, external gating systems, and external
interventional mechanisms such as abdominal compres-
sion and active breathing control systems.
Acceptance and commissioning
Acceptance testing and commissioning are essential
technical components of an SRS/SBRT program that must
be performed and documented completely and thoroughly
prior to clinical application. Acceptance testing is
performed in cooperation with an equipment vendor to
ensure that the equipment is operating within stated
specifications and in compliance with regulatory re-
quirements. As SRS/SBRT requires a high level of
precision in target and dose localization, it is necessary
for vendors to demonstrate that capabilities are commen-
surate with the requirements of SRS/SBRT.
Generally the commissioning task begins with the
measurement of the radiation characteristics of a
machine. Beam data acquisition is a common task
performed routinely by medical physicists.45 Acquisition
of beam data for SRS and SBRT can be particularly
challenging, however, due to the small size of the fields
employed, and small field measurements require appro-
priately small detectors.4,6 Further, small photon beams
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central axis, producing output factors that fall off rapidly
for fields below 10 mm in diameter.46,47 Due to the
profound clinical consequences of incorrect beam data
that are now well known in the recent media, this report
strongly recommends an independent assessment of
small field measurements. This could include compari-
son against published data, comparison against unpub-
lished data from similar treatment units, or by verifying
the data through a completely independent set of
measurements. Additionally, independent verification of
the absolute calibration, utilizing a service such as that
provided by the Radiologic Physics Center, is essential.
Following beam data acquisition, the treatment planning
system must be fully commissioned to ensure accurate
calculation of dose and monitor units. This involves a
systematic comparison of calculation and measurement
ranging from simple configurations such as a single
beam to sophisticated arrangements of beams encompass-
ing any and all situations encountered in clinical practice.
Ultimately, acceptance testing and commissioning must
be performed in a manner that assesses both the individual
and integrated localization and dosimetric components in
an end-to-end manner.4-6 This is stated very succinctly in
the Canadian Association of Provincial Cancer Agencies
stereotactic radiosurgery-radiotherapy standards [4]: qIt is
essential to recognize that commissioning SRS/T tech-
niques involves more than just ensuring that the equipment
itself works properly. The whole treatment chain,
including the measuring, imaging modalities and treatment
planning system must be tested in addition to the delivery
unit and the SRS/T tools.” This will most likely be
facilitated by incorporating appropriate, site-specific
anthropomorphic phantoms.The Quality Assurance Program
Quality assurance is an essential aspect of every
medical discipline, and the importance of a robust quality
assurance program to reduce errors of all kinds cannot be
overstated. In its Radiotherapy Risk Profile, the World
Health Organization states that proper QA measures are
imperative to reduce the likelihood of accidents and errors
and increase the probability that the errors will be
recognized and rectified if they do occur.7 ASTRO and
ACR guidelines are equally clear with regard to SRS and
SBRT QA: “Strict protocols for quality assurance must be
followed.”5 Additionally, as “the complexity, variation in
individual practice patterns, and continued evolution of
stereotactic-related technology can render a static, pre-
scriptive QA paradigm insufficient over time],”6 QA
activities must continually evolve. Programs must adhere
to a process of ongoing quality improvement, continually
evaluating the adequacy of policies and procedures. Eachof these elements is described in detail in the full version
of this report (online only at www.practicalradonc.org).Recommendations for stakeholders
While this report deals primarily with institutions and
professional staff, there are many stakeholders in the
safety/QA process, with common goals and shared
responsibilities. In this regard, improvement of patient
safety would be facilitated by collaborative efforts between
the manufacturers and the users, specifically in designing
safer systems, in developing QA methods and training
programs, and in promoting patient safety for SRS and
SBRT. Vendors must understand the needs and require-
ments of the clinicians, medical physicists and radiation
therapists relative to the systems and processes for SRS and
SBRT. With such understanding they must exert all the
necessary efforts to incorporate features and safeguards to
assure efficacious and safe operation of their products.
Vendors must provide additional opportunities for special-
ized training, emphasizing clinical implementation and
quality assurance in addition to technical aspects, and the
home institution must make available resources and time
for such training. Vendors must do more to emphasize all
QA aspects, not only equipment QA, but process QA. SRS/
SBRT systems consist of multiple components, and
vendors must ensure and demonstrate full mechanical,
electronic and information connectivity of these compo-
nents. In situations where components or subsystems come
from more than one manufacturer, it is the responsibilities
of the manufacturers to collaboratively support compati-
bility of the various subsystems, and their safe operation
when used in combination.
Professional organizations must also do more to
facilitate proper training in specialized procedures such
as SRS and SBRT, and to ensure that only qualified
practitioners are involved in such procedures. Specialized
accreditation programs may be an effective mechanism to
realize this, and extending ACR specialty accreditation to
SRS and SBRT would be a strong step in emphasizing and
recognizing practice quality. The current ACR-ASTRO
Radiation Oncology Accreditation Program should also
become mandatory. Professional organizations must work
closely with industry to enhance safety aspects of products
and practices.
There are many steps that government agencies can
take to enhance safety within the profession. There are
numerous inconsistencies in regulation and radiation-
event reporting between state and federal agencies, and
with regard to radioactive versus X-ray sources. The
findings of an earlier investigation on regulatory reform in
radiation medicine pointed out several areas of need, yet
many of the recommendations were never implemented.48
Centralized registries for event reporting, such as mandated
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transparency and provide an effective mechanism for all
stakeholders to learn from mistakes. Several voluntary
efforts currently exist, notably the Radiation Oncology
Safety Information System49 and the system implemented
at Washington University.50Summary
In summary, SRS and SBRT require a team-based
approach, staffed by appropriately trained and credentialed
specialists. SRS and SBRT training should become a
required part of radiation oncology residency training and
of Accreditation of Medical Physics Educational Programs
accredited clinical medical physics training. SRS and
SBRT require significant resources in personnel, special-
ized technology, and implementation time. A thorough
feasibility analysis of resources required to achieve the
clinical and technical goals must be performed and
discussed with all personnel, including medical center
administration. Because various disease sites may have
different clinical and technical requirements, feasibility
and planning discussions are needed prior to undertaking
new disease sites. Treatment of SRS/SBRT patients should
adhere to established national guidelines. Acceptance and
commissioning protocols and tests must be developed to
explore in detail every aspect of the individual and
integrated systems with the goal of ensuring safe and
effective operation. A comprehensive quality assurance
program, encompassing all clinical, technical, and patient-
specific treatment aspects, must be developed to ensure
SRS and SBRT are performed in a safe and effective
manner. Patient safety in radiation therapy is everyone's
responsibility. Professional organizations, regulators, ven-
dors, and end-users must demonstrate a clear commitment
to working closely together to ensure the highest levels of
safety and efficacy in stereotactic radiosurgery and
stereotactic body radiation therapy.Acknowledgments
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